A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease

PharmacoEconomics

Volumn 30, Issue 9, 2012, Pages 825-840

  Menn, Petra ^a   Leidl, Reiner ^a   Holle, Rolf ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Chronic obstructive pulmonary disease; Cost effectiveness; Cost utility; Health economics; Markov model; Smoking cessation therapies

Indexed keywords

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; ECONOMIC EVALUATION; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HEALTH STATUS; HIDDEN MARKOV MODEL; HUMAN; LIFE EXPECTANCY; LUNG FUNCTION; LUNG RESECTION; LUNG TRANSPLANTATION; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RISK; SMOKING; SMOKING CESSATION;

COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; GERMANY; HEALTH CARE COSTS; HUMANS; LUNG TRANSPLANTATION; MARKOV CHAINS; MODELS, ECONOMIC; PNEUMONECTOMY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY-ADJUSTED LIFE YEARS; SMOKING CESSATION;

EID: 84865025139     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11591340-000000000-00000     Document Type: Article

References (74)

1. GOLD: Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease. Bethesda (MD): National Institutes of Health, National Heart, Lung and Blood Institute, 2006
2. Rutten-Van Molken MP, Oostenbrink JB, Tashkin DP, et al. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 2006 Oct; 130 (4): 1117-1128 (Pubitemid 44583743)
3. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (The BOLD Study): A population-based prevalence study. Lancet 2007; 370 (9589): 741-750 (Pubitemid 47321907)
4. Nowak D, Dietrich ES, Oberender P, et al. Cost-of-illness study for the Treatment of COPD in Germany. Pneumologie 2004 Dec; 58 (12): 837-844 (Pubitemid 40069756)
5. WeiXbuch Lunge 2005. Die Lunge und ihre Erkrankungen; zur Lage und Zukunft der Pneumologie in Deutschland, 3rd edition. Stuttgart: Fabel, Helmut Thieme, 2005
6. Wedzicha JA, Seemungal TAR. COPD exacerbations: Defining their cause and prevention. Lancet 2007; 370 (9589): 786-796 (Pubitemid 47320802)
7. Hoogendoorn M, Rutten-Van Molken MP, Hoogenveen RT, et al. A dynamic population model of disease progression in COPD. Eur Respir J 2005 Aug; 26 (2): 223-233 (Pubitemid 41079065)
8. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998 Apr; 13 (4): 397-409 (Pubitemid 28140699)
9. Borg S, Ericsson A, Wedzicha J, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004 Mar-Apr; 7 (2): 153-167 (Pubitemid 38420728)
10. Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005; 23 (6): 619-637 (Pubitemid 40994129)
11. Oostenbrink JB, Rutten-Van Molken MP, Monz BU, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005 Jan-Feb; 8 (1): 32-46 (Pubitemid 40293639)
12. Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004 Mar; 116 (5): 325-331 (Pubitemid 38230292)
13. Chuck A, Jacobs P, Mayers I, et al. Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease. Can Respir J 2008 Nov-Dec; 15 (8): 437-443
14. Dal Negro R, Eandi M, Pradelli L, et al. Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients. Int J Chron Obstruct Pulmon Dis 2007; 2 (2): 169-176 (Pubitemid 47202217)
15. Earnshaw SR,WilsonMR, Dalal AA, et al. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respir Med 2009 Jan; 103 (1): 12-21
16. Zaniolo O, Iannazzo S, Pradelli L, et al. Pharmacoeconomic evaluation of tiotropium bromiDe in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy. Eur J Health Econ 2012 Feb; 13 (1): 71-80
17. Lang K, Wasem J, Aidelsburger P. Cost-effectiveness of nicotine replacement therapy (NRT) in patients with chronic obstructive pulmonary disease (COPD): A decision- analytic model. PharmacoEconomics - German Research Articles 2008; 6 (2): 111-123
18. Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: A review and consolidation of quality assessment. Pharmacoeconomics 2006; 24 (4): 355-371
19. Graf von der Schulenburg JM, Greiner W, Jost F, et al. German recommendations on health economic evaluation: Third and updated version of the Hanover Consensus. Value Health 2008 Jan; 11 (4): 539-44 (Pubitemid 352032814)
20. Menn P. [Einsatz entscheidungsanalytischer Modelle für die ökonomische Evaluation medizinischer Verfahren am Beispiel chronisch obstruktiver Lungenerkrankungen]. Munich: LMU, 2009 [online]. Available from URL: Http:// edoc.ub.uni-muenchen.de/10315/ [Accessed 2012 Jun 06]
21. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000 May; 117 (5 Suppl. 2): 398S-401S (Pubitemid 30314474)
22. Vestbo J. Epidemiology of exacerbations in chronic obstructive pulmonary disease. In: Siafakas N, Anthonisen NR, Georgopoulos D, editors. Acute exacerbations of chronic obstructive disease. New York: Marcel Dekker, 2004: 5-11
23. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002 Sep; 166 (5): 675-679 (Pubitemid 34971849)
24. (Pubitemid 30245717)
25. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.NEngl J Med 2007 Feb; 356 (8): 775-789 (Pubitemid 46294610)
26. Decramer M, Rutten-Van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): A randomised placebo-controlled trial. Lancet 2005; 365 (9470): 1552-1560 (Pubitemid 40615404)
27. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesoniDe in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 1999 May; 353 (9167): 1819-1823 (Pubitemid 29251012)
28. Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000 Feb; 161 (2 Pt 1): 381-390 (Pubitemid 30129442)
29. Sutton AJ, Abrams KR, Jones DR, et al. Methods for metaanalysis in medical research. New York: Wiley & Sons, 2000
30. Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998 Mar; 351 (9105): 773-780 (Pubitemid 28112338)
31. Keene ON, Calverley PMA, Jones PW, et al. Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. Eur Respir J 2008 Jul; 32 (1): 17-24
32. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2003 Feb; 361 (9356): 449-456 (Pubitemid 36173708)
33. Donaldson GC, Seemungal TA, Patel IS, et al. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 2003 Dec; 22 (6): 931-936 (Pubitemid 37540644)
34. Washko GR, Fan VS, Ramsey SD, et al. The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations.Am J Respir Crit Care Med 2008 Jan; 177 (2): 164-169
35. Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/ fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007 Jan; 175 (2): 144-149 (Pubitemid 46115085)
36. Prescott E, Osler M, Anderson PK, et al. Mortality in women and men in relation to smoking. Int J Epidemiol 1998 Feb; 27 (1): 27-32 (Pubitemid 28140499)
37. Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study.RespirMed 2006 Jan; 100 (1): 115-122 (Pubitemid 43039873)
38. National Emphysema Treatment Trial Research G. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003 May; 348 (21): 2059-2073
39. Geddes D, Davies M, Koyama H, et al. Effect of lungvolume-reduction surgery in patients with severe emphysema. N Engl J Med 2000 Jul; 343 (4): 239-245 (Pubitemid 30490391)
40. Hoogendoorn M, Feenstra TL, Schermer TR, et al. Severity distribution of chronic obstructive pulmonary disease (COPD) in Dutch general practice. Respir Med 2006 Jan; 100 (1): 83-86 (Pubitemid 43033383)
41. Stahl E, Lindberg A, Jansson SA, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005; 3 (1): 56
42. Miller JD, Malthaner RA, Goldsmith CH, et al. A randomized clinical trial of lung volume reduction surgery versus best medical care for patients with advanced emphysema: A two-year study from Canada. Ann Thorac Surg 2006 Jan; 81 (1): 314-20; discussion 20-21
43. Menn P, Weber N, Holle R. Health-related quality of life in patients with severe COPD hospitalized for exacerbations: Comparing EQ-5D, SF-12 and SGRQ. Health Qual Life Outcomes 2010; 8 (1): 39
44. Krauth C, Hessel F, Hansmeier T, et al. Empirical standard costs for health economic evaluation in Germany: A proposal by the Working Group Methods in Health Economic Evaluation. Gesundheitswesen 2005; 67 (10): 736-746 (Pubitemid 41604934)
45. Rutten-Van Molken MP, Oostenbrink JB, Miravitlles M, et al. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007 Jun; 8 (2): 123-135 (Pubitemid 46742896)
46. Koleva D, Motterlini N, Banfi P, et al. Healthcare costs of COPD in Italian referral centres: A prospective study. Respir Med 2007; 101 (11): 2312-2320 (Pubitemid 47495743)
47. Jansson SA, Andersson F, Borg S, et al. Costs of COPD in Sweden according to disease severity. Chest 2002 Dec; 122 (6): 1994-2002 (Pubitemid 36051135)
48. Institute for the Hospital Remuneration System [online]. Available from URL: Http://www.g-drg.De [Accessed 2007 Sep 21]
49. Littlefield C, Abbey S, Fiducia D, et al. Quality of life following transplantation of the heart, liver, and lungs. Gen Hosp Psychiatry 1996 Nov; 18 (6 Suppl.): 36S-47S (Pubitemid 26396803)
50. Statistisches Bundesamt. [Statistisches Jahrbuch 2007 für die Bundesrepublik Deutschland]. Wiesbaden; 2007 [online]. Available from URL: Https://www.destatis.de/DE/Pub likationen/StatistischesJahrbuch/Jahrbuch2007. pdf?-blob=publicationFile [Accessed 2012 Jun 17]
51. Donaldson GC, Seemungal TA, Wilkinson TM, et al. Exacerbation types by COPD severity; risk of hospitalisation by patients not seeking treatment [abstract]. Eur Respir J 2003; 22 Suppl.: 353s
52. Ramsey SD, Patrick DL, Albert RK, et al. The costeffectiveness of lung transplantation: A pilot study. Chest 1995 Dec; 108 (6): 1594-1601
53. Vasiliadis HM, Collet JP, Penrod JR, et al. A costeffectiveness and cost-utility study of lung transplantation. J Heart Lung Transplant 2005 Sep; 24 (9): 1275-1283 (Pubitemid 41247810)
54. Statistisches Bundesamt. [Todesursachen in Deutschland. Gestorbene in Deutschland an ausgewählten Todesursachen 2006]. Fachserie 12, Reihe 4 2007 [online]. Available from URL: Https://www.destatis.de/DE/Publikationen/Thema tisch/Gesundheit/Todesursachen/Todesursachen21204000 77004.pdf?-blob= publicationFile [Accessed 2012 Jun 17]
55. Neubauer S, Welte R, Beiche A, et al. Mortality, morbidity and costs attributable to smoking in Germany: Update and a 10-year comparison. Tob Control 2006 Dec; 15 (6): 464-471 (Pubitemid 44935574)
56. Connors Jr AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996 Oct; 154 (4 Pt 1): 959-967
57. Stamatis G. Operative Therapieverfahren. In: Lingner H, Schultz K, Schwartz FW, editors. Volkskrankheit Asthma/ COPD. Heidelberg: Springer, 2007; 239-245
58. Patel N, DeCamp M, Criner GJ. Lung transplantation and lung volume reduction surgery versus transplantation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008 May; 5 (4): 447-453 (Pubitemid 351669169)
59. Trulock EP, Christie JD, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth Official Adult Lung and Heart-Lung Transplantation Report, 2007. J Heart Lung Transplant 2007; 26 (8): 782-795 (Pubitemid 47199080)
60. Vogelmeier C, Buhl R, Criee CP, et al. Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft fur Pneumologie und Beatmungsmedizin zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie 2007 May; 61 (5): E1-40
61. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997 Nov; 35 (11): 1095-1108 (Pubitemid 127453463)
62. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994 Nov; 272 (19): 1497-1505
63. Weinstein MC, OBrien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 2003 Jan-Feb; 6 (1): 9-17 (Pubitemid 36228345)
64. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010 Sep; 363 (12): 1128-38
65. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006
66. Hammerschmidt T, Goertz A, Wagenpfeil S, et al. Validation of health economic models: The example of EVITA. Value Health 2003 Sep-Oct; 6 (5): 551-559 (Pubitemid 37187717)
67. Menn P, Holle R. Comparing three software tools for implementing markov models for health economic evaluations. Pharmacoeconomics 2009; 27 (9): 745-753
68. Greiner W, Weijnen T, Nieuwenhuizen M, et al. A single European currency for EQ-5D health states. Eur J Health Econ 2003; 4 (3): 222-231
69. Institute for Quality and Efficiency in Health Care. Working paper modelling. Version 1.0. - 20.11.2009 [online]. Available from URL: Https://www.iqwig.de/download/Work ing-Paper-Modelling.pdf [Accessed 2011 Feb 11]
70. Yi Y, Philips Z, Bergman G, et al. Economic models in type 2 diabetes. Curr Med Res Opin 2010 Sep; 26 (9): 2105-2118
71. Hoogendoorn M, Feenstra TL, Hoogenveen RT, et al. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax 2010; 65 (8): 711-718
72. Feenstra TL, Hamberg-Van Reenen HH, Hoogenveen RT, et al. Cost-effectiveness of face-to-face smoking cessation interventions: A dynamic modeling study. Value Health 2005 May-Jun; 8 (3): 178-190 (Pubitemid 41023477)
73. Hurley SF, Matthews JP. The Quit Benefits Model: A Markov model for assessing the health benefits and health care cost savings of quitting smoking. Cost Eff Resour Alloc 2007 Jan; 5 (1): 2
74. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004 Mar; 350 (10): 1005-1012(Pubitemid 38269277)